The RECORD and RAPTOR Clinical Trial Programs: Renal Cell Carcinoma Clinical Trial (RCC)
   
WIDE Program: Worldwide Initiative to Develop Everolimus
Print This Page   Email This Page
 
Novartis Oncology
Search :
 

Renal Cell Carcinoma - RCC
   » Home » Renal Cell Carcinoma - RCC
 

Everolimus ( RAD001) in Renal Cell Carcinoma (RCC): The RECORD & RAPTOR Programs

     
RECORD: REnal Cell cancer treatment with Oral RAD001 given Daily RAPTOR: RAD001 in Advanced Papillary Tumor prOgram in EuRope
 

What is the RECORD clinical trial program?


Novartis has initiated the RECORD (REnal Cell cancer treatment with Oral, RAD001 given Daily) clinical trial program to evaluate everolimus (RAD001) in RCC.
 
Currently, the RECORD clinical trial program comprises:
     RECORD-2 (To find out more about this renal cell carcinoma clinical trial, click here)
     RECORD-3 (To find out more about this renal cell carcinoma clinical trial, click here)
 

What is the RAPTOR clinical trial program?


Novartis has initiated the RAPTOR (RAD001 in Advanced Papillary Tumor PrOgram in EuRope) clinical trial program to evaluate everolimus (RAD001) in RCC.
 
Currently, the RAPTOR clinical trial program comprises:
     RAPTOR (To find out more about this renal cell carcinoma clinical trial, click here)
 
Disclaimer : These are investigational studies; there is no guarantee that everolimus will become commercially available for these indications
 
Disclaimer : This is an international web site for the The WIDE Program™ providing general information for healthcare professionals from all countries. The information on this site is not country-specific and may contain information that is different from where you practice. Please contact your local Novartis Medical Scientific Liaison for the latest information specific to your country.
Home | Renal Cell Carcinoma - RCC | Breast Cancer | Lymphoma - MCL & DLBCL | Tuberous Sclerosis Complex - TSC
Hepatocellular Carcinoma - HCC | Gastric Cancer | About Novartis | Tell a Colleague
Contact Us | Site Map | Terms of Use | Privacy Policy © 2010 Novartis AG